We helped Reuters connect with GLP-1 patients to highlight real-world struggles with affordability and access. These voices brought depth and urgency to their national coverage, ensuring that the human impact of policy and pricing shifts was impossible to ignore.
This newsletter is owned and produced by GLP-1 Studio LLC, a separate for-profit platform that shares updates in support of the GLP-1 Collective nonprofit.
Subscriptions are optional, free unless you choose paid, and not tax-deductible.
